Insider Transactions in Q1 2023 at Nuvectis Pharma, Inc. (NVCT)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 27
2023
|
Enrique Poradosu Chief Science & Business Off |
BUY
Open market or private purchase
|
Direct |
500
+0.04%
|
$5,500
$11.55 P/Share
|
|
Mar 23
2023
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
230
+0.01%
|
$2,760
$12.13 P/Share
|
|
Mar 21
2023
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
480
+0.01%
|
$5,760
$12.08 P/Share
|
|
Mar 21
2023
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Open market or private purchase
|
Direct |
420
+0.03%
|
$4,620
$11.99 P/Share
|
|
Mar 15
2023
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Open market or private purchase
|
Direct |
670
+0.05%
|
$6,700
$10.71 P/Share
|
|
Mar 15
2023
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
480
+0.01%
|
$4,800
$10.91 P/Share
|
|
Mar 14
2023
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
1,680
+0.05%
|
$16,800
$10.85 P/Share
|
|
Jan 12
2023
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
115,000
+7.79%
|
-
|
|
Jan 12
2023
|
Ron Bentsur Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
210,000
+6.11%
|
-
|
|
Jan 12
2023
|
Enrique Poradosu Chief Science & Business Off |
BUY
Grant, award, or other acquisition
|
Direct |
115,000
+7.73%
|
-
|